Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577993 · ClinicalTrials.gov registry record · Phase 3
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
NCT00577993: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00577993 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 210 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00577993, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to compare chemotherapy given with rituximab to chemotherapy followed by rituximab. The safety of both treatment schedules will be studied. Laboratory tests of genetic changes in blood and bone marrow before and during the study will also be monitored.
Primary Outcome
Overall Survival is the time from date of treatment start until date of death due to any cause or last Follow-up within 10 years.
Interventions
- DRUG Fludarabine
- DRUG Rituximab
- DRUG Decadron
- DRUG Interferon
- DRUG Novantrone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 1998-03-16 |
| Est. Completion | 2017-08-24 |
| Phase | Phase 3 |
What the finished NCT00577993 record still lists
NCT00577993 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00577993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00577993 about?
NCT00577993 is a clinical study titled "Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients". The goal of this clinical research study is to compare chemotherapy given with rituximab to chemotherapy followed by rituximab. The safety of both treatment schedules will be studied. Laboratory tests of genetic changes in blood and bone marrow before and during the study will also be monitored.
What is the current status of trial NCT00577993?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 1998-03-16. Estimated completion is 2017-08-24.
What interventions are being tested in trial NCT00577993?
The interventions under investigation include: Fludarabine (DRUG), Rituximab (DRUG), Decadron (DRUG), Interferon (DRUG), Novantrone (DRUG).
Who is sponsoring clinical trial NCT00577993?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00577993's enrollment target sits among peer trials
210 1338th of 2000 higher than 656 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI